Newborn Screening Market by Technology (High Performance Liquid Chromatography, Immunoassay, Molecular Techniques), Test Type (Cystic Fibrosis, Endocrine Disorders, Hemoglobin Disorders), End User, Sample Type - Global Forecast 2025-2032
Description
The Newborn Screening Market was valued at USD 1.06 billion in 2024 and is projected to grow to USD 1.16 billion in 2025, with a CAGR of 9.06%, reaching USD 2.13 billion by 2032.
Emerging Innovations in Newborn Screening Are Reshaping Early Diagnosis and Intervention Strategies with Unprecedented Technological Advancements
Newborn screening has emerged as a cornerstone of pediatric healthcare, fundamentally transforming the approach to early disease detection. By analyzing biomarkers through advanced analytical techniques shortly after birth, healthcare providers can identify conditions that would otherwise remain undetected until clinical symptoms manifest, often at irreversible cost. This proactive model not only reduces morbidity and mortality associated with congenital disorders, but also paves the way for targeted interventions that improve both immediate and long-term patient outcomes.
As scientific innovation accelerates, the newborn screening landscape is evolving from limited panels focused on a handful of disorders to expansive protocols encompassing dozens of genetic and metabolic anomalies. This expansion is driven by continuous improvements in assay sensitivity, specificity, and throughput, enabling the reliable detection of rare conditions at scale. With regulatory bodies worldwide endorsing broader screening recommendations, stakeholders across the public and private sectors are collaborating to refine testing guidelines, optimize laboratory workflows, and ensure equitable access to these life-saving services.
Paradigm Shift in Newborn Screening Drives Integration of High Throughput Technologies and Data Driven Approaches to Enhance Clinical Outcomes
Over the past decade, newborn screening has undergone transformative shifts, propelled by breakthroughs in both analytical instrumentation and informatics. Laboratories have moved beyond single-analyte assays to adopt multiplexed platforms that deliver comprehensive metabolic profiles from minimal sample volumes. The integration of tandem mass spectrometry and next generation sequencing into routine workflows has unlocked unprecedented diagnostic reach, enabling the simultaneous screening of dozens of inborn errors of metabolism and rare genetic disorders with remarkable accuracy.
Concurrently, digital health solutions and data analytics have emerged as critical enablers of program expansion. Real-time data exchange between hospital systems, diagnostic laboratories, and public health registries has streamlined result reporting and follow-up management. Machine learning algorithms now assist in interpreting complex data patterns, reducing false positives and guiding confirmatory testing protocols. These advances are fostering a more personalized approach to newborn care, where early risk stratification and targeted intervention plans are tailored to the unique genetic and biochemical profiles of each infant. As a result, the field is transitioning from reactive diagnostics to predictive and preventive newborn healthcare.
Shifting Trade Policies and Tariff Implementation Create Complexities across Newborn Screening Value Chains and Supply Logistics Impacting Efficiency
The implementation of new United States tariff measures in 2025 has introduced a layer of complexity across the newborn screening ecosystem. Many of the specialized reagents, precision instruments, and sample preparation kits essential to laboratory operations are produced abroad, exposing diagnostic providers to increased import duties. As a result, operating costs have risen, prompting laboratories to re-evaluate procurement strategies and negotiate alternative supply agreements to mitigate the impact on testing affordability.
In response to these challenges, industry leaders have diversified sourcing models, exploring near-shore manufacturing partnerships and qualifying additional suppliers to ensure continuity of reagent availability. Laboratories have also accelerated efforts to optimize existing workflows, investing in automation and lean process methodologies to offset higher material expenses. At the same time, strategic collaborations with government agencies have emerged to secure tariff exemptions for critical public health commodities. These cumulative measures are helping to safeguard the stability of newborn screening programs while preserving access to timely diagnostic results for at-risk infants.
Comprehensive Market Segmentation Reveals Distinct Opportunities across Technology Platforms Test Categories End User Environments and Sample Types
A multifaceted segmentation analysis illuminates the diverse opportunities and operational nuances within the newborn screening domain. Technological platforms vary from established high performance liquid chromatography and immunoassay systems to increasingly adopted molecular techniques, which include polymerase chain reaction and Sanger sequencing, as well as cutting-edge next generation sequencing and tandem mass spectrometry. Each technology offers distinct advantages in terms of sensitivity, throughput, and cost per test, shaping the diagnostic panels implemented by healthcare networks.
Test categorization further differentiates the market, with cystic fibrosis, endocrine disorders, hemoglobinopathies, and inborn errors of metabolism representing core focus areas. Laboratories tailor their assay portfolios based on regional prevalence and clinical screening mandates, optimizing resource allocation to align with public health priorities. End users range from dedicated diagnostic laboratories equipped with specialized instrumentation to hospital and clinic laboratories integrating these services into broader patient care pathways, as well as research laboratories advancing novel assay development and validation.
Moreover, the choice of sample matrix-whether dried blood spots or serum samples-affects both logistics and analytical performance. Dried blood spot testing remains the industry standard for its minimal specimen volume requirements and ease of transport, while serum-based assays offer complementary biomarker detection capabilities. Understanding these interrelated segmentation dimensions is critical for stakeholders seeking to design end-to-end solutions that enhance both diagnostic coverage and operational efficiency.
Diverse Regional Dynamics Highlight Unique Drivers and Challenges in the Americas Europe Middle East Africa and Asia Pacific Newborn Screening Markets
Regional dynamics in newborn screening are shaped by distinct policy frameworks, healthcare infrastructures, and disease prevalence patterns. In the Americas, established public health programs leverage centralized laboratories to provide standardized screening panels, supported by sustained government funding and comprehensive follow-up networks. The mature market exhibits a growing emphasis on integrating genomic data and expanding the scope of detectable conditions.
Within Europe, the Middle East, and Africa, the landscape is more heterogeneous. Several European nations maintain robust screening initiatives with uniform protocols, while emerging markets in the Middle East and segments of Africa are undertaking phased rollouts driven by international collaborations and capacity-building programs. The focus in these regions often includes bolstering laboratory capabilities, establishing training frameworks, and securing sustainable supply chains to ensure long-term program viability.
In the Asia-Pacific region, rapid population growth and rising healthcare investment are accelerating the adoption of both traditional and advanced screening methodologies. National and private laboratories are increasingly incorporating tandem mass spectrometry and next generation sequencing into their testing arsenals. Governments and healthcare payers are also evaluating policy incentives to broaden insurance coverage, thereby extending the benefits of early detection to a wider demographic.
Strategic Profiles of Leading Innovators Showcase How Global Industry Players Are Driving Technological Advances Operational Excellence and Growth
Leading industry participants are driving innovation through strategic investments in research and development, digital transformation, and cross-sector partnerships. Global life science companies are introducing highly automated sample processing systems and multiplexed assay kits to streamline laboratory operations and reduce turnaround times. Biotechnology firms specializing in genomic technologies have secured strategic alliances with clinical laboratories to validate and commercialize novel sequencing protocols tailored for neonatal screening.
In parallel, diagnostic equipment manufacturers are enhancing instrument interoperability and integrating cloud-based data solutions to support remote monitoring and quality control. Collaborative platforms are emerging that connect diagnostic providers, software developers, and research institutions to foster the co-creation of next generation screening workflows. These initiatives demonstrate a collective commitment to refining the precision, reliability, and scalability of newborn screening services worldwide.
Targeted Strategic Imperatives Provide Roadmap for Industry Leaders to Accelerate Innovation Strengthen Partnerships and Enhance Newborn Screening Outcomes
Industry leaders should prioritize the integration of multiomic approaches by combining biochemical and genomic assays to deliver a more holistic screening portfolio. Establishing strategic alliances with reagent producers and instrument vendors can secure preferential access to cutting-edge consumables and co-development opportunities for novel assay formats. Simultaneously, engaging with regulatory authorities to advocate for streamlined approval pathways will accelerate the introduction of expanded screening panels.
Operational excellence can be further enhanced by adopting advanced data analytics and artificial intelligence to interpret complex diagnostic outputs, reduce follow-up delays, and optimize laboratory resource utilization. Strengthening cross-functional collaboration between neonatal units, genetic counselors, and public health officials will improve care coordination and patient education. Finally, exploring innovative financing models, such as outcome-based reimbursement and public-private partnerships, will help ensure the long-term sustainability of newborn screening programs while enabling broader access to life-saving diagnostics.
Rigorous Research Framework Integrates Expert Interviews Secondary Data Analysis and Triangulation Methods to Deliver Actionable Insights into Newborn Screening
This analysis is underpinned by a rigorous research framework that integrates expert interviews with clinicians, laboratory directors, industry executives, and public health policymakers. Comprehensive secondary data analysis draws on peer-reviewed literature, regulatory filings, clinical guidelines, and published technical specifications to corroborate primary insights. Triangulation methods are applied to validate findings and identify convergent themes across diverse data sources.
Each segmentation dimension and regional market characteristic is evaluated through cross‐referenced evidence, ensuring the robustness of our conclusions. Quality assurance protocols, including validation workshops with domain experts, reinforce the credibility of the research. This multifaceted approach delivers actionable intelligence designed to inform strategic planning and operational decision making within the newborn screening ecosystem.
Synthesis of Critical Discoveries Emphasizes Strategic Imperatives and Collaborative Efforts to Advance Newborn Screening Programs and Improve Patient Care
In synthesizing the critical discoveries, it becomes clear that newborn screening is at an inflection point defined by technological innovation, policy evolution, and strategic collaboration. The convergence of high throughput analytical platforms with advanced data analytics is enabling more comprehensive and equitable screening programs. While new tariff measures have introduced operational challenges, they have also catalyzed supply chain resilience and procurement innovation.
Moving forward, stakeholders across the public and private sectors must align around shared objectives to expand diagnostic coverage, improve patient outcomes, and ensure program sustainability. By leveraging the insights presented herein, decision makers can chart a course that balances rapid adoption of breakthrough technologies with pragmatic considerations of cost, regulation, and resource allocation. This holistic perspective will pave the way for the next generation of newborn screening excellence.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Technology
High Performance Liquid Chromatography
Immunoassay
Molecular Techniques
Polymerase Chain Reaction
Sanger Sequencing
Next Generation Sequencing
Tandem Mass Spectrometry
Test Type
Cystic Fibrosis
Endocrine Disorders
Hemoglobin Disorders
Inborn Errors Of Metabolism
End User
Diagnostic Laboratories
Hospitals And Clinics
Research Laboratories
Sample Type
Dried Blood Spot
Serum Sample
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
PerkinElmer, Inc.
Thermo Fisher Scientific Inc.
Danaher Corporation
Agilent Technologies, Inc.
Waters Corporation
Abbott Laboratories
Bio-Rad Laboratories, Inc.
BioMérieux SA
Siemens Healthineers AG
Shimadzu Corporation
Please Note: PDF & Excel + Online Access - 1 Year
Emerging Innovations in Newborn Screening Are Reshaping Early Diagnosis and Intervention Strategies with Unprecedented Technological Advancements
Newborn screening has emerged as a cornerstone of pediatric healthcare, fundamentally transforming the approach to early disease detection. By analyzing biomarkers through advanced analytical techniques shortly after birth, healthcare providers can identify conditions that would otherwise remain undetected until clinical symptoms manifest, often at irreversible cost. This proactive model not only reduces morbidity and mortality associated with congenital disorders, but also paves the way for targeted interventions that improve both immediate and long-term patient outcomes.
As scientific innovation accelerates, the newborn screening landscape is evolving from limited panels focused on a handful of disorders to expansive protocols encompassing dozens of genetic and metabolic anomalies. This expansion is driven by continuous improvements in assay sensitivity, specificity, and throughput, enabling the reliable detection of rare conditions at scale. With regulatory bodies worldwide endorsing broader screening recommendations, stakeholders across the public and private sectors are collaborating to refine testing guidelines, optimize laboratory workflows, and ensure equitable access to these life-saving services.
Paradigm Shift in Newborn Screening Drives Integration of High Throughput Technologies and Data Driven Approaches to Enhance Clinical Outcomes
Over the past decade, newborn screening has undergone transformative shifts, propelled by breakthroughs in both analytical instrumentation and informatics. Laboratories have moved beyond single-analyte assays to adopt multiplexed platforms that deliver comprehensive metabolic profiles from minimal sample volumes. The integration of tandem mass spectrometry and next generation sequencing into routine workflows has unlocked unprecedented diagnostic reach, enabling the simultaneous screening of dozens of inborn errors of metabolism and rare genetic disorders with remarkable accuracy.
Concurrently, digital health solutions and data analytics have emerged as critical enablers of program expansion. Real-time data exchange between hospital systems, diagnostic laboratories, and public health registries has streamlined result reporting and follow-up management. Machine learning algorithms now assist in interpreting complex data patterns, reducing false positives and guiding confirmatory testing protocols. These advances are fostering a more personalized approach to newborn care, where early risk stratification and targeted intervention plans are tailored to the unique genetic and biochemical profiles of each infant. As a result, the field is transitioning from reactive diagnostics to predictive and preventive newborn healthcare.
Shifting Trade Policies and Tariff Implementation Create Complexities across Newborn Screening Value Chains and Supply Logistics Impacting Efficiency
The implementation of new United States tariff measures in 2025 has introduced a layer of complexity across the newborn screening ecosystem. Many of the specialized reagents, precision instruments, and sample preparation kits essential to laboratory operations are produced abroad, exposing diagnostic providers to increased import duties. As a result, operating costs have risen, prompting laboratories to re-evaluate procurement strategies and negotiate alternative supply agreements to mitigate the impact on testing affordability.
In response to these challenges, industry leaders have diversified sourcing models, exploring near-shore manufacturing partnerships and qualifying additional suppliers to ensure continuity of reagent availability. Laboratories have also accelerated efforts to optimize existing workflows, investing in automation and lean process methodologies to offset higher material expenses. At the same time, strategic collaborations with government agencies have emerged to secure tariff exemptions for critical public health commodities. These cumulative measures are helping to safeguard the stability of newborn screening programs while preserving access to timely diagnostic results for at-risk infants.
Comprehensive Market Segmentation Reveals Distinct Opportunities across Technology Platforms Test Categories End User Environments and Sample Types
A multifaceted segmentation analysis illuminates the diverse opportunities and operational nuances within the newborn screening domain. Technological platforms vary from established high performance liquid chromatography and immunoassay systems to increasingly adopted molecular techniques, which include polymerase chain reaction and Sanger sequencing, as well as cutting-edge next generation sequencing and tandem mass spectrometry. Each technology offers distinct advantages in terms of sensitivity, throughput, and cost per test, shaping the diagnostic panels implemented by healthcare networks.
Test categorization further differentiates the market, with cystic fibrosis, endocrine disorders, hemoglobinopathies, and inborn errors of metabolism representing core focus areas. Laboratories tailor their assay portfolios based on regional prevalence and clinical screening mandates, optimizing resource allocation to align with public health priorities. End users range from dedicated diagnostic laboratories equipped with specialized instrumentation to hospital and clinic laboratories integrating these services into broader patient care pathways, as well as research laboratories advancing novel assay development and validation.
Moreover, the choice of sample matrix-whether dried blood spots or serum samples-affects both logistics and analytical performance. Dried blood spot testing remains the industry standard for its minimal specimen volume requirements and ease of transport, while serum-based assays offer complementary biomarker detection capabilities. Understanding these interrelated segmentation dimensions is critical for stakeholders seeking to design end-to-end solutions that enhance both diagnostic coverage and operational efficiency.
Diverse Regional Dynamics Highlight Unique Drivers and Challenges in the Americas Europe Middle East Africa and Asia Pacific Newborn Screening Markets
Regional dynamics in newborn screening are shaped by distinct policy frameworks, healthcare infrastructures, and disease prevalence patterns. In the Americas, established public health programs leverage centralized laboratories to provide standardized screening panels, supported by sustained government funding and comprehensive follow-up networks. The mature market exhibits a growing emphasis on integrating genomic data and expanding the scope of detectable conditions.
Within Europe, the Middle East, and Africa, the landscape is more heterogeneous. Several European nations maintain robust screening initiatives with uniform protocols, while emerging markets in the Middle East and segments of Africa are undertaking phased rollouts driven by international collaborations and capacity-building programs. The focus in these regions often includes bolstering laboratory capabilities, establishing training frameworks, and securing sustainable supply chains to ensure long-term program viability.
In the Asia-Pacific region, rapid population growth and rising healthcare investment are accelerating the adoption of both traditional and advanced screening methodologies. National and private laboratories are increasingly incorporating tandem mass spectrometry and next generation sequencing into their testing arsenals. Governments and healthcare payers are also evaluating policy incentives to broaden insurance coverage, thereby extending the benefits of early detection to a wider demographic.
Strategic Profiles of Leading Innovators Showcase How Global Industry Players Are Driving Technological Advances Operational Excellence and Growth
Leading industry participants are driving innovation through strategic investments in research and development, digital transformation, and cross-sector partnerships. Global life science companies are introducing highly automated sample processing systems and multiplexed assay kits to streamline laboratory operations and reduce turnaround times. Biotechnology firms specializing in genomic technologies have secured strategic alliances with clinical laboratories to validate and commercialize novel sequencing protocols tailored for neonatal screening.
In parallel, diagnostic equipment manufacturers are enhancing instrument interoperability and integrating cloud-based data solutions to support remote monitoring and quality control. Collaborative platforms are emerging that connect diagnostic providers, software developers, and research institutions to foster the co-creation of next generation screening workflows. These initiatives demonstrate a collective commitment to refining the precision, reliability, and scalability of newborn screening services worldwide.
Targeted Strategic Imperatives Provide Roadmap for Industry Leaders to Accelerate Innovation Strengthen Partnerships and Enhance Newborn Screening Outcomes
Industry leaders should prioritize the integration of multiomic approaches by combining biochemical and genomic assays to deliver a more holistic screening portfolio. Establishing strategic alliances with reagent producers and instrument vendors can secure preferential access to cutting-edge consumables and co-development opportunities for novel assay formats. Simultaneously, engaging with regulatory authorities to advocate for streamlined approval pathways will accelerate the introduction of expanded screening panels.
Operational excellence can be further enhanced by adopting advanced data analytics and artificial intelligence to interpret complex diagnostic outputs, reduce follow-up delays, and optimize laboratory resource utilization. Strengthening cross-functional collaboration between neonatal units, genetic counselors, and public health officials will improve care coordination and patient education. Finally, exploring innovative financing models, such as outcome-based reimbursement and public-private partnerships, will help ensure the long-term sustainability of newborn screening programs while enabling broader access to life-saving diagnostics.
Rigorous Research Framework Integrates Expert Interviews Secondary Data Analysis and Triangulation Methods to Deliver Actionable Insights into Newborn Screening
This analysis is underpinned by a rigorous research framework that integrates expert interviews with clinicians, laboratory directors, industry executives, and public health policymakers. Comprehensive secondary data analysis draws on peer-reviewed literature, regulatory filings, clinical guidelines, and published technical specifications to corroborate primary insights. Triangulation methods are applied to validate findings and identify convergent themes across diverse data sources.
Each segmentation dimension and regional market characteristic is evaluated through cross‐referenced evidence, ensuring the robustness of our conclusions. Quality assurance protocols, including validation workshops with domain experts, reinforce the credibility of the research. This multifaceted approach delivers actionable intelligence designed to inform strategic planning and operational decision making within the newborn screening ecosystem.
Synthesis of Critical Discoveries Emphasizes Strategic Imperatives and Collaborative Efforts to Advance Newborn Screening Programs and Improve Patient Care
In synthesizing the critical discoveries, it becomes clear that newborn screening is at an inflection point defined by technological innovation, policy evolution, and strategic collaboration. The convergence of high throughput analytical platforms with advanced data analytics is enabling more comprehensive and equitable screening programs. While new tariff measures have introduced operational challenges, they have also catalyzed supply chain resilience and procurement innovation.
Moving forward, stakeholders across the public and private sectors must align around shared objectives to expand diagnostic coverage, improve patient outcomes, and ensure program sustainability. By leveraging the insights presented herein, decision makers can chart a course that balances rapid adoption of breakthrough technologies with pragmatic considerations of cost, regulation, and resource allocation. This holistic perspective will pave the way for the next generation of newborn screening excellence.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Technology
High Performance Liquid Chromatography
Immunoassay
Molecular Techniques
Polymerase Chain Reaction
Sanger Sequencing
Next Generation Sequencing
Tandem Mass Spectrometry
Test Type
Cystic Fibrosis
Endocrine Disorders
Hemoglobin Disorders
Inborn Errors Of Metabolism
End User
Diagnostic Laboratories
Hospitals And Clinics
Research Laboratories
Sample Type
Dried Blood Spot
Serum Sample
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
PerkinElmer, Inc.
Thermo Fisher Scientific Inc.
Danaher Corporation
Agilent Technologies, Inc.
Waters Corporation
Abbott Laboratories
Bio-Rad Laboratories, Inc.
BioMérieux SA
Siemens Healthineers AG
Shimadzu Corporation
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
196 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Expansion of next-generation sequencing panels to detect rare genetic disorders in newborns
- 5.2. Integration of digital health platforms for real time data sharing and follow up in newborn screening
- 5.3. Public private partnerships driving nationwide expansions of newborn screening infrastructure in underserved regions
- 5.4. Adoption of point of care testing solutions to accelerate metabolic disorder detection in rural clinics
- 5.5. Harmonization of policies and reimbursement frameworks to support uniform newborn screening across states
- 5.6. Emerging metabolomic biomarkers enabling broader multiplex newborn screening for inborn errors of metabolism
- 5.7. Utilization of artificial intelligence algorithms for interpreting complex genomic variants in neonatal screening
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Newborn Screening Market, by Technology
- 8.1. High Performance Liquid Chromatography
- 8.2. Immunoassay
- 8.3. Molecular Techniques
- 8.3.1. Polymerase Chain Reaction
- 8.3.2. Sanger Sequencing
- 8.4. Next Generation Sequencing
- 8.5. Tandem Mass Spectrometry
- 9. Newborn Screening Market, by Test Type
- 9.1. Cystic Fibrosis
- 9.2. Endocrine Disorders
- 9.3. Hemoglobin Disorders
- 9.4. Inborn Errors Of Metabolism
- 10. Newborn Screening Market, by End User
- 10.1. Diagnostic Laboratories
- 10.2. Hospitals And Clinics
- 10.3. Research Laboratories
- 11. Newborn Screening Market, by Sample Type
- 11.1. Dried Blood Spot
- 11.2. Serum Sample
- 12. Newborn Screening Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Newborn Screening Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Newborn Screening Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. PerkinElmer, Inc.
- 15.3.2. Thermo Fisher Scientific Inc.
- 15.3.3. Danaher Corporation
- 15.3.4. Agilent Technologies, Inc.
- 15.3.5. Waters Corporation
- 15.3.6. Abbott Laboratories
- 15.3.7. Bio-Rad Laboratories, Inc.
- 15.3.8. BioMérieux SA
- 15.3.9. Siemens Healthineers AG
- 15.3.10. Shimadzu Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
